Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Rohan J. K. Hettiarachchi"'
Publikováno v:
Thrombosis and Haemostasis. 82:1600-1604
SummaryClinical and experimental studies have suggested that unfractionated heparin (UFH) effects malignancy progression. We reviewed all published clinical reports concerning the effects of UFH, as compared to no treatment on survival of cancer pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64094ca0fa3dc35a155aca8fdd6f050b
https://doi.org/10.1055/s-0037-1614885
https://doi.org/10.1055/s-0037-1614885
Autor:
Rohan J. K. Hettiarachchi, Mark Levine, Susanne M. Smorenburg, Harry R. Büller, Jeffrey S. Ginsberg, Martin H. Prins
Publikováno v:
Thrombosis and Haemostasis. 82:947-952
IntroductionThe influence of unfractionated heparin (UFH) and other anticoagulants on the spread of cancer has been reported since the early 1960s.1 However, clinical studies investigating the use of heparins in cancer patients have not produced cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9dccdb2e9b576a97ce7182c3d47c087
https://doi.org/10.1055/s-0037-1615937
https://doi.org/10.1055/s-0037-1615937
Autor:
Ron J.G. Peters, Rohan J. K. Hettiarachchi, Marcel Levi, Martin H. Prins, Nick R. Bijsterveld, H. R. Büller
Publikováno v:
Thrombosis and haemostasis, 82(Suppl. 1), 139-147. Schattauer GmbH
Summary Introduction: Since the introduction of low-molecular-weight heparins (LMWHs) in the early 1980's, the use of these compounds has been extensively investigated as a substitute for unfractionated heparin (UFH) in patients with venous and arter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e11ec88f31fb66e11ea3b9f8512b2e5
https://doi.org/10.1055/s-0037-1615573
https://doi.org/10.1055/s-0037-1615573
Publikováno v:
Current Opinion in Pulmonary Medicine. 4:220-225
In this review, we analyze data from randomized trials in which low molecular weight heparin was compared with unfractionated heparin, both to estimate the treatment effect of low molecular weight heparin in the initial treatment of venous thromboemb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::318f34c8ccf4d1958d955df716d54200
https://doi.org/10.1097/00063198-199807000-00007
https://doi.org/10.1097/00063198-199807000-00007
Publikováno v:
Cancer, 83(1), 180-185. John Wiley and Sons Inc.
BACKGROUND The reported incidence of a subsequent diagnosis of malignancy in patients presenting with deep vein thrombosis (DVT) varies from 2-25%. Risk indicators and diagnostic procedures to be performed in these patients are controversial. METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a0d4ebffc531427c9497f47bb3363ae
https://doi.org/10.1002/(sici)1097-0142(19980701)83:1<180::aid-cncr24>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19980701)83:1<180::aid-cncr24>3.0.co
Autor:
CA Hoefnagel, B StJacques, Jareer Kassis, Krystyna Kinnon, Terri Finch, M Berger, E Ascari, F. Turkstra, J Stanford, M Escribano, Mmw Koopman, Judy Kovacs, D ElKouri, Agg Turpie, J vanderMeer, Antonio Girolami, Eki Code, PM Manucci, Beverly Morrow, Paolo Bucciarelli, A vanBarneveld, Susan Haley, Sergio Siragusa, Paul Ockelford, Manuel Monreal, G Garrido, P Nguyen, Marco Moia, D Cohlan, S Bornais, D. P. M. Brandjes, M Barone, B Girolami, Dianne Donovan, Sabina Villalta, S Roy, E Lafoz, Ejr vanBeek, S Serafini, Judith Johnson, L Biagioni, B Petiteau, Patrick Brill-Edwards, L Rossi, Beng H. Chong, L Wilkinson, MA Pistorius, Jeffrey S. Ginsberg, B Planchon, P Bagatella, M vonLewinski, J Jagot, Sylvia Haas, Moira Cruickshank, YP Graafsma, R. Baildon, Michael Gent, Awa Lensing, J. I. Weitz, Christine Demers, JN Fiesinger, Richard M. Jay, Alexander Gallus, William Geerts, Gth Que, S Finkenbine, Clive Kearon, C N Chesterman, Eleanor Boyle, L Couture, L LIberale, Anderson, LT Eimers, C Rich, G Simonneau, F Parent, WM Smid, Pmm Kuijer, B Palmer, R Faivre, J CoteDesjardins, KS Robinson, F Lossner, WM Brien, K Redekop, [No Value] Cusson, M deRijk, Paolo Prandoni, T Bynon, James D. Douketis, D Goudie, Janis Bormanis, [No Value] Leclerc, Louis Desjardins, C Beltrametti, JW tenCate, H Jagt, Martin H. Prins, Michael J. Kovacs, FA Spengel, S Whittaker, M Ruel, H. R. Büller, P. S. Wells, Franco Piovella, Jack Hirsh, John Cade, Barbara A. Hutten, J Poulin, JC Sahuquillo, J Villenueve, Jgp Tijssen, Rohan J. K. Hettiarachchi, S Pritchard
Publikováno v:
ResearcherID
New England journal of medicine, 337(10), 657-662. Massachussetts Medical Society
New England Journal of Medicine, 337(10), 657-662. MASSACHUSETTS MEDICAL SOC
New England journal of medicine, 337(10), 657-662. Massachussetts Medical Society
New England Journal of Medicine, 337(10), 657-662. MASSACHUSETTS MEDICAL SOC
Background Low-molecular-weight heparin is known to be safe and effective for the initial Treatment of patients with proximal deep-vein thrombosis. However, its application to patients with pulmonary embolism or previous episodes of thromboembolism h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c7f58e0e396bc0ad92779304b542835
https://doi.org/10.1056/nejm199709043371001
https://doi.org/10.1056/nejm199709043371001
Publikováno v:
Thrombosis and Haemostasis. 78:121-125
The incidence of newly diagnosed malignancy is increased in patients with unexplained venous thromboembolism during the first year after a thromboembolic event in comparison to controls (odds ratio, 3.9-36). Extensive screening with computed tomograp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b5ab64ca03fc52d4181e5c094a22711
https://doi.org/10.1055/s-0038-1657513
https://doi.org/10.1055/s-0038-1657513
Autor:
Antonio Girolami, Bruno Girolami, J W ten Cate, Enrico Bernardi, Paolo Prandoni, H. R. Büller, Rohan J. K. Hettiarachchi, MH Prins
Publikováno v:
Archives of internal medicine. 159(4)
Background There is no consensus on the efficacy of physical training, smoking cessation, and pharmacological therapy (pentoxifylline or nafronyl oxalate) in the treatment of patients with intermittent claudication at Fontaine stage II of disease. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f71256901c52f9d05f7dc5db3649269
https://pubmed.ncbi.nlm.nih.gov/10493329
https://pubmed.ncbi.nlm.nih.gov/10493329
Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis
Autor:
Rohan J. K. Hettiarachchi, E Marras, Antonio Girolami, Bruno Girolami, P. M. Stefani, Paolo Prandoni, H. R. Büller, J W ten Cate, MH Prins, Enrico Bernardi
Publikováno v:
Thrombosis and haemostasis, 81(5), 715-722. Schattauer GmbH
Summary Background. There is no consensus on the efficacy of the antithrombotic drugs available for patients with intermittent claudication. Methods. A Medline and manual search was used to identify relevant publications. Uncontrolled or retrospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b726a837a334b247e994b6e4052b1806
http://hdl.handle.net/11577/2467620
http://hdl.handle.net/11577/2467620
